, Volume 4, Issue 4, pp 173–177 | Cite as

Refined mapping of the Welander distal myopathy region on chromosome 2p13 positions the new candidate region telomeric of the DYSF locus

  • Désirée von Tell
  • Carl E. G. Bruder
  • Louise V. B. Anderson
  • Maria Anvret
  • Gabrielle Åhlberg
Original Article


Welander distal myopathy (WDM) is a late adult-onset autosomal dominant disorder, characterized by a slow progression and distal limb weakness of the extremity muscles. The WDM locus has been mapped to chromosome 2p13. Within this region a common shared haplotype co-segregates in all affected patients, indicating a founder effect. By undertaking an extended linkage analysis we have significantly reduced the WDM locus to a critical interval of approximately 1.2 Mb flanked by markers D2S358 and PAC3-H52. The dysferlin gene, a strong candidate gene responsible for two other distal myopathies in the same region, is located centromeric to PAC3-H52 and can thereby formally be excluded as cause for WDM.


Welander Distal myopathy Refined mapping 2p13 Dysferlin 



We wish to thank all the family members who participated in this study. The work was supported by grants from the Swedish Medical Research Council, the Torsten and Ragnar Söderberg Foundation, The Swedish Association of Neurologically Disabled, Karolinska Insitutet, and Augusta and Petrus Hedlunds Foundation, and approved by the Karolinska Hospital Ethics Committee. We thank Dr. Cilla Söderhäll for revision of the linkage analysis.


  1. 1.
    Ahlberg G, et al (1998) Welander hereditary distal myopathy, a molecular genetic comparison to hereditary myopathies with inclusion bodies. Neuromuscul Disord 8:111–114CrossRefPubMedGoogle Scholar
  2. 2.
    Ahlberg G, et al (1999) Genetic linkage of Welander distal myopathy to chromosome 2p13. Ann Neurol 46:399–404CrossRefPubMedGoogle Scholar
  3. 3.
    Ahlberg G, et al (1997) Welander distal myopathy is not linked to other defined distal myopathy gene loci. Neuromuscul Disord 7:256–260CrossRefPubMedGoogle Scholar
  4. 4.
    Liu J, et al (1998) Generation of a 3-Mb PAC contig spanning the Miyoshi myopathy/limb-girdle muscular dystrophy (MM/LGMD2B) locus on chromosome 2p13. Genomics 49:23–29CrossRefPubMedGoogle Scholar
  5. 5.
    Bashir R, et al (1996) Genetic and physical mapping at the limb-girdle muscular dystrophy locus (LGMD2B) on chromosome 2p. Genomics 33:46–52CrossRefPubMedGoogle Scholar
  6. 6.
    Liu J, et al (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20:31–36Google Scholar
  7. 7.
    Bashir R, et al (1998) A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 20:37–42Google Scholar
  8. 8.
    Ahlberg G, et al (1994) Distribution of muscle degeneration in Welander distal myopathy a magnetic resonance imaging and muscle biopsy study. Neuromuscul Disord 4:55–62CrossRefPubMedGoogle Scholar
  9. 9.
    Tell D von, et al (2002) Welander distal myopathy outside the Swedish population: phenotype and genotype. Neuromuscul Disord 12:544–547CrossRefPubMedGoogle Scholar
  10. 10.
  11. 11.
  12. 12.
    Kruglyak L, et al (1996) Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 58:1347–1363PubMedGoogle Scholar
  13. 13.
    Anderson LV (1999) Immunomarkers for molecular mass. Neuromuscul Disord 9:421–422CrossRefPubMedGoogle Scholar
  14. 14.
    Weiler T, et al (1999) Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). Hum Mol Genet 8:871–877Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Désirée von Tell
    • 1
    • 2
    • 3
  • Carl E. G. Bruder
    • 3
  • Louise V. B. Anderson
    • 4
  • Maria Anvret
    • 5
  • Gabrielle Åhlberg
    • 1
    • 2
  1. 1.Department of Clinical NeuroscienceKarolinska HospitalStockholmSweden
  2. 2.Department of Molecular MedicineKarolinska HospitalStockholmSweden
  3. 3.Transgenics and Comparative GenomicsAstraZeneca R and DSweden
  4. 4.Department of Neurobiology and NeurologyUniversity Medical SchoolNewcastle upon TyneUK
  5. 5.AstraZeneca R and DSweden

Personalised recommendations